Contact
Please use this form to send email to PR contact of this press release:
Nohla Receives EMA PRIME Designation for Dilanubicel (NLA101) to Treat Hematopoietic Stem Cell Transplant Patients
TO:
Please use this form to send email to PR contact of this press release:
Nohla Receives EMA PRIME Designation for Dilanubicel (NLA101) to Treat Hematopoietic Stem Cell Transplant Patients
TO: